Abstract

To evaluate the role of MM creatine kinase isoforms in detecting infarct vessel patency in 84 patients with acute myocardial infarction, total creatine kinase, MB creatine kinase, and MM isoforms were determined at the start of thrombolytic therapy and 30, 60, and 120 minutes later. Enzyme data were related to the reperfusion grade of the infarct artery, which was assessed by angiography 60 and 90 minutes after the start of thrombolysis. In 50 patients the infarct vessel was found patent at 60 and at 90 minutes after thrombolysis; in 19 patients it was occluded at both time points. In contrast to the patients with a persistently occluded infarct artery, in the patient group with a patent infarct vessel total creatine kinase and MB creatine kinase increased significantly at 60 minutes after the start of thrombolysis and MM 3 creatine kinase activity and the ratio MM 3:MM 1 had already increased at 30 minutes after the start of thrombolytic therapy. The increases from baseline of creatine kinase and creatine kinase MB activity were significantly higher 120 minutes after the start of thrombolysis; increases of creatine kinase MM 3 and the ratio of MM 3:MM 1, however, by 60 minutes after the start of thrombolysis were already increased compared with the increases in enzyme activity in patients with an occluded artery. Thus the rise in MM 3 creatine kinase and the ratio of MM 3:MM 1 can be used for early detection of reperfusion after intravenous thrombolytic therapy in acute myocardial infarction.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.